There’s a good deal of momentum with Second Sight Medical Products (EYES).
Over the last few days, all eyes were on EYES, as it exploded from a low of $1.40 to $14.83. Volume is now up to 160 million, as compared to daily average volume of 14.3 million. All on news the US FDA approved its Argus 2s Retinal Prosthesis System.
According to the company, the System is, “a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company expects that the Argus 2s will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System currently under development.”
In addition, according to acting CEO, Matthew Pfeffer, “We are very pleased to have received this approval, as it presents an opportunity to offer external hardware that we believe enhance comfort and aesthetics compared with the legacy Argus II system.”
With a good deal of momentum, volume, and potential interest following US FDA approval, keep an eye on EYES. It could see higher highs moving forward.
